Ceribell (CBLL) CRO Joseph Manni sells $32,691 in shares

Chief Revenue Officer Joseph S. Manni of Ceribell, Inc. (CBLL) divested 1,361 shares of the company's stock on August 21, 2026, for a total of $32,691. The shares were sold at $24.02 per share, coinciding with Ceribell's stock trading near its 52-week high of $25.33, which represents a 109% return over the past year. The transaction was executed to satisfy tax withholding requirements related to the vesting of restricted stock units.

Post-sale, Manni now directly owns 55,956 shares of Ceribell common stock, including 1,026 shares acquired through the company’s Employee Stock Purchase Plan on July 31, 2026. While Ceribell boasts a robust balance sheet with more cash than debt and impressive gross profit margins of 88.9%, InvestingPro analysts indicate the stock might be overvalued at the current level.

Interested investors can access a comprehensive Pro Research Report on Ceribell among 1,400+ reports available on InvestingPro. Ceribell reported robust financial results for the second quarter of fiscal 2026, with revenue increasing by 33% to $28.1 million compared to the prior year. Although the company reported a loss of $0.51 per share, which exceeded the expected $0.36 loss, its expansion in seizure-detection technology, new products for delirium monitoring, and pediatric care has garnered investor interest.

Following the earnings report, Canaccord raised its price target for Ceribell to $26 from $25 and maintained a Buy rating, citing the company's strong same-store utilization and recent account additions. BTIG also increased its price target to $30 from $28, highlighting Ceribell's growth outlook and leadership in point-of-care rapid EEG technology.

Both analysts have reaffirmed their Buy ratings, underscoring confidence in Ceribell's market position and future potential. This report was AI-generated and reviewed by an editor.